# New COVID-19 clinical trials: 268 posted since Nov 2024

Updated October 27, 2026.

268 clinical studies in COVID-19 were first posted on ClinicalTrials.gov from November 12, 2024 to October 27, 2026; 78 have an industry sponsor and 81 are recruiting or about to. The newest, NCT07899346, was posted on October 27, 2026: Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome (Invivyd, Inc.).

## The full list

New COVID-19 clinical trials: 268 rows for $13.40, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/covid-19

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 268
- Industry sponsored: 78
- Recruiting or not yet: 81
- Latest posted: October 27, 2026

## Newest trials

The newest 100 of 268, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07899346 | Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome | Invivyd, Inc. | Phase 2 | Not yet recruiting | Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine, COVID Long | 130 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899346) |
| October 23, 2026 | NCT07892872 | Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections | Capital Medical University | Not applicable | Not yet recruiting | Respiratory Viral Infections, Influenza, SARS CoV 2 Infection | 618 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892872) |
| October 20, 2026 | NCT07882186 | Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the... | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Vaccination Coverage Among Pregnant Women | 1,605 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882186) |
| October 15, 2026 | NCT07875270 | Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test | CorDx, Inc. | Not applicable | Not yet recruiting | SARS-CoV-2 Infection, Influenza A, Influenza B, RSV | 1,500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875270) |
| October 13, 2026 | NCT07871448 | Flu COVID Vaccine Views | George Washington University | Observational | Not yet recruiting | Influenza, COVID-19, Vaccination Willingness | 550 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871448) |
| October 7, 2026 | NCT07863635 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | ModernaTX, Inc. | Phase 4 | Recruiting | SARS-CoV-2 | 600 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863635) |
| October 6, 2026 | NCT07861542 | Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 | Sanofi | Phase 4 | Recruiting | COVID-19 | 660 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861542) |
| October 2, 2026 | NCT07856576 | Effect of a Social-Support-Based Educational Intervention on COVID-19-Related Anxiety and Perceived Social Support in Pregnant Women: A... | Atefeh Dehnoalian | Not applicable | Completed | Pregnancy, Anxiety, COVID-19, Social Support | 110 | Iran | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856576) |
| October 2, 2026 | NCT07856225 | Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Fundación Santa Fe de Bogota | Observational | Recruiting | Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer | 370 | Colombia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856225) |
| September 28, 2026 | NCT07845396 | Assessment of Stress and Associated Factors Among Young Adults During the COVID-19 Pandemic | GCS Ramsay Santé pour l'Enseignement et la Recherche | Observational | Completed | Anxiety, Stress, COVID - 19 | 1,322 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845396) |
| September 24, 2026 | NCT07838363 | Online Pain Management Programmes During the Covid-19 Pandemic | Walton Centre NHS Foundation Trust | Observational | Completed | Pain Management | 30 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838363) |
| September 22, 2026 | NCT07834073 | Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 | Completed | COVID-19, SARS-CoV-2 Infection | 2,052 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834073) |
| September 11, 2026 | NCT07816471 | RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed Adults | Hospital Italiano de Buenos Aires | Observational | Active not recruiting | Respiratory Syncytial Virus Infections, Immunocompromised Host, Influenza, COVID - 19 | 350 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816471) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | Argentina, Dominican Republic, Mexico, Panama, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| September 1, 2026 | NCT07798648 | A Study of COVID-19 Vaccine(s) in Children and Adults | BioNTech SE | Phase 3 | Recruiting | COVID-19 Vaccines | 700 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798648) |
| August 27, 2026 | NCT07791186 | Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years | BMI Korea | Phase 1 | Not yet recruiting | Prevention of COVID-19 Variant (Omicron JN.1) | 72 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791186) |
| August 27, 2026 | NCT07790523 | Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax \[mRNA-1083\]) in Adults ≥ 65 Years | Tor Biering-Sørensen | Phase 4 | Not yet recruiting | COVID-19, Influenza | 410,000 | Denmark, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790523) |
| August 24, 2026 | NCT07781501 | Long-Term Study of COVID-19 Infection and Long COVID | University of North Carolina, Chapel Hill | Observational | Recruiting | SARS CoV-2 Post-Acute Sequelae | 500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781501) |
| August 14, 2026 | NCT07766512 | Five-year Follow-up After Sars-CoV-2 Infection: Prevalence and Evolution of Post-acute Sequalae of COVID-19 (PASC) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Long COVID, COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Post-Acute COVID-19 | 900 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766512) |
| August 12, 2026 | NCT07760701 | Description of the Lived Experiences of Family Caregivers for People With Mental Health Comorbidities | Centre for Infectious Disease Research in Zambia | Observational | Completed | Depression, Anxiety, Trauma | 30 | Zambia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760701) |
| August 11, 2026 | NCT07758309 | Online Games to Help Canadian and U.S. Adults Identify COVID-19 and Vaccine Misinformation: Three Sequential Randomized Studies | University of South Carolina | Not applicable | Completed | COVID-19, Vaccine Hesitancy, Health Misinformation, Communication | 3,637 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758309) |
| August 11, 2026 | NCT07758296 | An Online Game to Help Canadian Adults Identify COVID-19 Vaccine Misinformation With One-Month Follow-Up | University of South Carolina | Not applicable | Completed | COVID-19, Vaccination Hesitancy, Health Misinformation, Communication | 4,071 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758296) |
| August 11, 2026 | NCT07757620 | Epigenetic Changes in Long COVID Patients | Istituti Clinici Scientifici Maugeri SpA | Observational | Active not recruiting | Long COVID-19 Syndrome, Long COVID Symptoms | 1,000 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757620) |
| August 5, 2026 | NCT07746544 | Study of Secutrelvir in Participants With COVID-19 | Shionogi | Phase 3 | Recruiting | COVID-19 | 1,200 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746544) |
| August 4, 2026 | NCT07743970 | Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia | Biocrucible Ltd | Not applicable | Active not recruiting | SARS CoV 2 Infection, Influenza A Virus Infection, Influenza B Virus Infection | 500 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743970) |
| August 4, 2026 | NCT07743580 | A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease | Shionogi | Phase 3 | Recruiting | SARS-CoV-2 | 2,000 | Bulgaria, Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743580) |
| July 31, 2026 | NCT07739446 | Effect of Surgical Masks in Preventing Acute Respiratory Infections | Chiba University | Not applicable | Enrolling by invitation | Acute Respiratory Infections (ARIs), Influenza, COVID - 19 | 2,400 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739446) |
| July 28, 2026 | NCT07730450 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | BioNTech SE | Phase 4 | Recruiting | COVID-19 Vaccines | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730450) |
| July 27, 2026 | NCT07729241 | COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival | Groupe Hospitalier Pitie-Salpetriere | Observational | Completed | Cancer, Immune Checkpoint Inhibitors, COVID-19 Vaccination, Survival | 95,015 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729241) |
| July 27, 2026 | NCT07728396 | A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults | GC Biopharma Corp | Phase 1 | Active not recruiting | COVID - 19 | 72 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728396) |
| July 23, 2026 | NCT07722000 | Different Treatment Options Used for Post Covid-19 Syndrome | Beni-Suef University | Not applicable | Completed | COVID-19, Post COVID-19 Syndrome, Ginkgo Biloba, Piracetam | 90 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722000) |
| July 22, 2026 | NCT07720596 | Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era | Charles University, Czech Republic | Observational | Completed | COVID-19, SARS-CoV-2 | 1,795,570 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720596) |
| July 22, 2026 | NCT07719166 | Treatment and Outcomes in Patients With COVID-19 and Competing Acute Surgical Diseases in Moscow | Pirogov Russian National Research Medical University | Observational | Completed | COVID-19, Emergency Surgery, Abdominal Surgery, Real-World Data | 58,000 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719166) |
| July 17, 2026 | NCT07711444 | The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID... | National Science and Technology Council, Taiwan | Not applicable | Completed | COVID - 19, Depression - Major Depressive Disorder | 54 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711444) |
| July 16, 2026 | NCT07709637 | Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients | LucasBio | Phase 1 | Active not recruiting | COVID-19, COVID-19 (SARS-CoV-2 Infection) | 1 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709637) |
| July 14, 2026 | NCT07703475 | A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | COVID -19 | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703475) |
| July 8, 2026 | NCT07690943 | Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients | LucasBio | Not applicable | Completed | COVID-19, COVID-19 (SARS-CoV-2 Infection) | 13 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690943) |
| July 1, 2026 | NCT07678619 | Smart Analysis and Decision-Making for Emerging Infectious Diseases | Peking University | Not applicable | Enrolling by invitation | Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox), Dengue Fever, Chikungunya Fever, Avian Influenza | 108 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678619) |
| June 24, 2026 | NCT07664696 | Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19... | Kimera Labs Inc. | Phase 1/2 | Not yet recruiting | COVID-19 | 64 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664696) |
| June 22, 2026 | NCT07659847 | Cardiovascular Assessment 5 Years After MIS-C | Medical University of Warsaw | Observational | Recruiting | Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection | 90 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659847) |
| June 18, 2026 | NCT07656610 | Respiratory Muscle Training and Walking Exercise in Women Recovering From COVID-19 Pneumonia | Hitit University | Not applicable | Completed | COVID-19 Pneumonia, Respiratory Symptoms | 80 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656610) |
| June 17, 2026 | NCT07655180 | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine | Invivyd, Inc. | Phase 3 | Completed | COVID-19 | 210 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655180) |
| June 16, 2026 | NCT07651761 | Patient-Centered Practical Vaccine Talk For Busy Clinicians | University of Massachusetts, Worcester | Not applicable | Enrolling by invitation | Influenza, COVID-19 | 24,500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651761) |
| June 11, 2026 | NCT07643688 | Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections | Fabiana Sherine Ganem dos Santos | Observational | Not yet recruiting | SARS CoV 2 Infection, RSV Infections, Influenza Infection | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643688) |
| June 10, 2026 | NCT07640308 | Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 1 | Not yet recruiting | Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus) | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640308) |
| June 8, 2026 | NCT07633366 | BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics | Medical University of Vienna | Observational | Recruiting | ARDS (Acute Respiratory Distress Syndrome) | 130 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633366) |
| June 4, 2026 | NCT07627815 | Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID | ParagonClinicals Inc. | Phase 2 | Recruiting | Long COVID | 82 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627815) |
| May 28, 2026 | NCT07610512 | Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines | Grape King Bio Ltd. | Not applicable | Completed | COVID-19, Immune Response | 138 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610512) |
| May 20, 2026 | NCT07599449 | Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France | Institut National de la Santé Et de la Recherche Médicale, France | Observational | Recruiting | Respiratory Tract Infections (RTI), Influenza -Like Illness, Influenza, COVID - 19, RSV Infections, Rhinovirus... | 25,000 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599449) |
| May 19, 2026 | NCT07597889 | Diagnostic Accuracy of 2 cm Versus 4 cm Insertion Depth for Nasal Swabs for SARS-CoV-2 (COVID-19) Rapid Antigen Testing-A Randomized... | Copenhagen University Hospital, Rigshospitalet | Not applicable | Completed | COVID -19 | 317 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597889) |
| May 19, 2026 | NCT07597876 | SMAtteo COvid19 REgistry (SMACORE) | Fondazione IRCCS Policlinico San Matteo di Pavia | Observational | Recruiting | COVID-19 | 1,000 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597876) |
| May 6, 2026 | NCT07571421 | Effect of a Visual Educational Intervention on Dental Anxiety in Children | Istanbul University | Not applicable | Completed | Dental Anxiety in Children | 70 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571421) |
| May 6, 2026 | NCT07569523 | Development of Preterm Infants Born During the COVID-19 Pandemic | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Observational | Not yet recruiting | Preterm Infant Development, COVID - 19 | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569523) |
| April 30, 2026 | NCT07560059 | Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV) | Algerian Society of Diabetology | Observational | Completed | Diabetes Mellitus, COVID-19, Post-Acute COVID-19 Syndrome | 201 | Algeria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560059) |
| April 27, 2026 | NCT07552779 | A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir | Pfizer | Phase 1 | Completed | Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory... | 17 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552779) |
| April 17, 2026 | NCT07536308 | A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Active not recruiting | COVID-19 | 83 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07536308) |
| April 14, 2026 | NCT07527130 | C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome | Mayo Clinic | Observational | Not yet recruiting | COVID-19 | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527130) |
| April 9, 2026 | NCT07518771 | PA-001 Ph.1 Study in Healthy and Elderly Subjects | PeptiDream Inc. | Phase 1 | Completed | COVID - 19 | 47 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518771) |
| April 8, 2026 | NCT07516977 | Noseguard for Prevention of Respiratory Infections in Real-World Use | Daewoong Pharmaceutical Co. LTD. | Not applicable | Not yet recruiting | Respiratory Infection Virus, COVID-19, Influenza | 2,000 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516977) |
| April 1, 2026 | NCT07505953 | The Effects of Operating Room COVID-19 Personal Protective Equipment on Speech Perception and Listening Effort | Ondokuz Mayıs University | Observational | Completed | Speech Perception, Communication Barriers, Operating Rooms, Protective Devices | 219 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07505953) |
| March 31, 2026 | NCT07504341 | Physiological Finding in Management of COVID 19 Patients | St. Martin De Porress Hospital | Observational | Recruiting | COVID-19 (Coronavirus Disease 2019) | 15,000 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07504341) |
| March 24, 2026 | NCT07490314 | Blood Product Supply | Methodist Health System | Observational | Completed | COVID-19 | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490314) |
| March 12, 2026 | NCT07466524 | suPAR Michigan M2C2 Heterogeneity Validation Cohort Study | ViroGates A/S | Observational | Completed | COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome | 367 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07466524) |
| March 11, 2026 | NCT07464314 | A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults | GlaxoSmithKline | Phase 1 | Recruiting | Influenza, Human+COVID-19 | 225 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464314) |
| March 5, 2026 | NCT07450833 | Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers | Benfovir AG | Phase 1 | Completed | Healthy Volunteers | 48 | Bulgaria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07450833) |
| March 3, 2026 | NCT07445971 | A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. | ModeX Therapeutics, An OPKO Health Company | Phase 1 | Recruiting | COVID -19, COVID-19 (Prevention) | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445971) |
| February 27, 2026 | NCT07436572 | Neural Network-Based Prediction in Critical COVID-19 Patients | University of Gaziantep | Observational | Completed | COVID-19 Pandemic | 113 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436572) |
| February 27, 2026 | NCT07436494 | Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs | Bursa City Hospital | Observational | Completed | COVID-19, Anxiety, Rheumatic Diseases | 200 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436494) |
| February 24, 2026 | NCT07430410 | Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test | CorDx, Inc. | Not applicable | Not yet recruiting | SARS-CoV-2 Infection, Influenza A, Influenza B | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430410) |
| February 18, 2026 | NCT07416539 | Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19 | Rokote Laboratories Finland Oy | Phase 1 | Active not recruiting | COVID - 19, SARS CoV-2 | 20 | Finland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416539) |
| February 17, 2026 | NCT07412574 | Vitamin E Supplementation As Adjunctive Therapy To Lower Inflammation In COVID-19 Patients | Universidad Veracruzana | Early phase 1 | Completed | COVID - 19 | 56 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412574) |
| February 13, 2026 | NCT07408297 | Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in... | Victoria Biomedical Research Institute | Phase 2 | Completed | COVID -19, SARS CoV 2 Infection | 1,919 | Kenya | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07408297) |
| February 12, 2026 | NCT07406217 | OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients | Calmy Alexandra | Phase 2 | Recruiting | COVID-19, Immunodeficiency | 256 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406217) |
| February 9, 2026 | NCT07397455 | Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants | Imperial College London | Phase 1 | Recruiting | SARS-CoV-2 (COVID-19) | 38 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397455) |
| February 9, 2026 | NCT07397156 | Long-Term Outcomes After ICU-Treated COVID-19 ARDS | University in Zielona Góra | Observational | Completed | COVID-19, ARDS (Acute Respiratory Distress Syndrome) | 283 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397156) |
| February 5, 2026 | NCT07388550 | Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | Not yet recruiting | Post-Acute COVID-19 Syndrome | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388550) |
| February 4, 2026 | NCT07387211 | Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region | The Institute of Molecular and Translational Medicine, Czech Republic | Not applicable | Completed | SARS-CoV-2, SARS-CoV-2 (COVID-19) Infection | 2,484 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387211) |
| January 20, 2026 | NCT07352462 | Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath | Hospices Civils de Lyon | Not applicable | Not yet recruiting | Respiratory Infections, COVID-19, Influenza Virus Infection, Legionella Pneumophila Infections | 777 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07352462) |
| January 20, 2026 | NCT07352072 | Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal... | Copenhagen University Hospital, Rigshospitalet | Observational | Not yet recruiting | VV ECMO, Bleeding, Thrombosis, Transfusion Adverse Reaction, COVID-19 | 50 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07352072) |
| January 13, 2026 | NCT07337382 | The Optimising Isolation, Quarantine and Distancing Study for COVID-19 | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | Observational | Active not recruiting | COVID19 | 1,000 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07337382) |
| January 9, 2026 | NCT07328399 | Impact of COVID-19 Pandemic Waves on Colorectal Cancer Stage Migration and Diagnostic Delays | University of Pecs | Observational | Completed | Colorectal Cancer | 198 | Hungary | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328399) |
| January 2, 2026 | NCT07314905 | Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | Unity Health Toronto | Phase 3 | Recruiting | Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs) | 264 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314905) |
| January 2, 2026 | NCT07314593 | Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults. | Landspitali University Hospital | Not applicable | Recruiting | Respiratory Infections | 400 | Iceland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314593) |
| December 29, 2025 | NCT07308158 | Covid Flu A/B and RSV 4 in 1 Diagnostic Test | iHealth Labs inc | Observational | Completed | Influenza A, Influenza B, COVID - 19, RSV | 1,119 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308158) |
| December 24, 2025 | NCT07302295 | Analysis of Suicidal Behavior Among Children and Adolescents in the Auvergne-Rhone-Alpes Region During the Covid 19 Pandemic Period | Hospices Civils de Lyon | Not applicable | Recruiting | Suicidality, COVID -19 | 6,500 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302295) |
| December 24, 2025 | NCT07300839 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | BioNTech SE | Phase 3 | Completed | COVID-19, SARS-COV-2 Infection | 5,240 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300839) |
| December 23, 2025 | NCT07298434 | Study of VYD2311 for the Prevention of COVID-19 | Invivyd, Inc. | Phase 3 | Active not recruiting | COVID-19 | 1,770 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07298434) |
| December 17, 2025 | NCT07287137 | Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study | Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 | Recruiting | COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection... | 54 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287137) |
| December 12, 2025 | NCT07279766 | Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors... | Tor Biering-Sørensen | Phase 4 | Completed | COVID-19 | 41,060 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279766) |
| December 5, 2025 | NCT07266558 | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions... | ModernaTX, Inc. | Phase 4 | Active not recruiting | SARS-CoV-2 | 30,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07266558) |
| December 3, 2025 | NCT07262450 | Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms | Laboratoire de la Mer | Not applicable | Recruiting | URTI, Bronchiolitis, COVID - 19, Allergic Rhinitis, Chronic Rhinosinusitis (CRS), Post-surgery | 1,065 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262450) |
| December 3, 2025 | NCT07261085 | A Study to Learn How Paxlovid \[Nirmatrelvir-ritonavir/PF-07321332\] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions. | Pfizer | Observational | Completed | COVID-19 | 99,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261085) |
| November 28, 2025 | NCT07254442 | Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing | Zonguldak Bulent Ecevit University | Observational | Completed | Hearing, COVID - 19, Ototoxicity | 90 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254442) |
| November 25, 2025 | NCT07248319 | Production and Evaluation of an Evidence-based Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases... | Lebanese American University | Not applicable | Not yet recruiting | Produce and Evaluate an Evidence-based Health Awareness Video | 160 | Lebanon | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07248319) |
| November 24, 2025 | NCT07244731 | The Prognostic Role of Red Blood Cell Distribution (RDW) in Severe COVID-19 Patients | Ankara University | Observational | Completed | COVID - 19, Prognosis, ICU | 146 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244731) |
| November 19, 2025 | NCT07235137 | A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults | Pfizer | Phase 1 | Completed | Healthy Participant | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235137) |
| October 29, 2025 | NCT07222384 | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at... | BioNTech SE | Phase 3 | Completed | COVID-19, SARS-COV-2 Infection | 344 | Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222384) |
| October 27, 2025 | NCT07221162 | A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Active not recruiting | COVID-19 | 140 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221162) |
| October 16, 2025 | NCT07217639 | Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings | Aptitude Medical Systems | Not applicable | Not yet recruiting | COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus | 2,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217639) |
| October 10, 2025 | NCT07215520 | Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults | CastleVax Inc. | Phase 2 | Active not recruiting | COVID-19 | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215520) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Pfizer | 11 | April 27, 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 8 | July 14, 2026 |
| BioNTech SE | 7 | September 1, 2026 |
| ModernaTX, Inc. | 6 | October 7, 2026 |
| Shionogi | 5 | August 5, 2026 |
| Invivyd, Inc. | 3 | October 27, 2026 |
| Assistance Publique - Hôpitaux de Paris | 3 | October 20, 2026 |
| Centre for Infectious Disease Research in Zambia | 3 | August 12, 2026 |
| Fondazione IRCCS Policlinico San Matteo di Pavia | 3 | May 19, 2026 |
| Hospices Civils de Lyon | 3 | January 20, 2026 |
| Ankara University | 3 | November 24, 2025 |
| CorDx, Inc. | 2 | October 15, 2026 |
| Sanofi | 2 | October 6, 2026 |
| Tor Biering-Sørensen | 2 | August 27, 2026 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2 | August 14, 2026 |
| University of South Carolina | 2 | August 11, 2026 |
| Beni-Suef University | 2 | July 23, 2026 |
| LucasBio | 2 | July 16, 2026 |
| Institut National de la Santé Et de la Recherche Médicale, France | 2 | May 20, 2026 |
| Copenhagen University Hospital, Rigshospitalet | 2 | May 19, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 105 | October 20, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 69 | October 23, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 34 | August 27, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 18 | October 27, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 18 | September 1, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 11 | October 7, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 9 | June 24, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 3 | February 17, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | August 14, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 83 | October 15, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 22 | June 18, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 18 | October 20, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 16 | October 23, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 15 | August 11, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 14 | August 27, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 9 | August 27, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 7 | July 17, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 6 | August 5, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 6 | September 30, 2025 |
| [Puerto Rico](https://specstream.ai/data/clinical-trials/country/puerto-rico) | 5 | September 9, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 5 | August 27, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 5 | June 4, 2026 |
| [Zambia](https://specstream.ai/data/clinical-trials/country/zambia) | 4 | August 12, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 4 | July 23, 2026 |
| [Colombia](https://specstream.ai/data/clinical-trials/country/colombia) | 3 | October 2, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 3 | September 24, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 3 | September 9, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 3 | September 9, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 3 | August 4, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 3 | July 22, 2026 |
| [Russia](https://specstream.ai/data/clinical-trials/country/russia) | 3 | July 22, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 3 | June 22, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 3 | April 27, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 3 | February 12, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).